Biosergen AB operates as a biopharmaceutical company. It focuses on the clinical development of the antifungal product BSG005, is a potentially disruptive antifungal drug used for the treatment of life threatening invasive fungal disease. The company is headquartered in Solna, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company